EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 6, 2010, Pages 1238-1250

  Hindorf, Cecilia ^a   Glatting, Gerhard ^b   Chiesa, Carlo ^c   Lindén, Ola ^d   Flux, Glenn ^e  

^a LUNAM UNIVERSITÉ   (France)

^b UNIVERSITY OF ULM   (Germany)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bone marrow; Internal dosimetry; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; DOTATOC Y 90; ETIDRONIC ACID RE 186; IBRITUMOMAB IN 111; IBRITUMOMAB TIUXETAN; LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT; SODIUM IODIDE I 131; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

BLOOD SAMPLING; BONE MARROW; BONE MARROW CELL; CANCER THERAPY; DATA ANALYSIS; DOSIMETRY; EXTRACELLULAR FLUID; HUMAN; PRACTICE GUIDELINE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; WHOLE BODY RADIATION;

BLOOD CELLS; BONE MARROW; EUROPE; EXTRACELLULAR SPACE; IMAGE PROCESSING, COMPUTER-ASSISTED; NUCLEAR MEDICINE; RADIATION DOSAGE; RADIOMETRY; SOCIETIES, MEDICAL; TIME FACTORS; WHOLE BODY IMAGING;

EID: 77954886801     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1422-4     Document Type: Review

References (75)

1. Wahl RL, Zasadny K, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39(8 Suppl): 21S-7S.
2. 90Y-antibody therapy. J Nucl Med 2002;43(9):1245-53.
3. Wessels BW, Bolch WE, Bouchet LG, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004;45(10):1725-33.
4. 177Lu-DOTA (0), Tyr (3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36(7):1138-46.
5. Breitz HB, Fisher DR, Wessels BW. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med 1998;39(10):1746-51.
6. Shen S, Meredith RF, Duan J, et al. Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy. Cancer Biother Radiopharm 2003;18(2):209-15.
7. O'Donoghue JA, Baidoo N, Deland D, et al. Hematologic toxicity in radioimmunotherapy: Dose-response relationships for 131-I labeled antibody therapy. Cancer Biother Radiopharm 2002;17(4):435-43.
8. Behr T, Béhé M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm 2002;17(4):445-64.
9. Hindorf C, Lindén O, Tennvall J, et al. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy. Acta Oncol 2005;44:579-88.
10. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematologic toxicity and absorbed dose to bone marrow. Acta Oncol 2002;41(3):297-303.
11. International Commission on Radiological Protection, Basic anatomical and physiological data for use in radiological protection: the skeleton. 1995, Pergamon: Oxford, UK
12. International Commission on Radiological Protection, Basic anatomical and physiological data for use in radiological protection: reference values. 2002, Pergamon: Oxford, UK
13. Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981;26(3):389-400.
14. Bradley EW. Bone marrow physiology and radiobiology. Antibody Immunoconjug Radiopharm 1990;3(4):289-91.
15. Fliedner TM, Graessle D, Paulsen C, et al. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm 2002;17(4):405-26.
16. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine; 1991.
17. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD Pamphlet No 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40(2):37s-61s.
18. Chittenden S, Pratt BE, Pomeroy K, et al. Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm 2007;22(2):243-9.
19. He B, Wahl RL, Du Y, et al. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning - Monte Carlo simulation studies. IEEE Trans Med Imaging 2008;27(4):521-30.
20. 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma. J Nucl Med 2000;41(9):1579-86.
21. 124I PET and 3-dimensionalinternal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366-72.
22. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med 2009;50(11):1844-7.
23. 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:1337-45.
24. Ogawa K, Harata Y, Ichihara T, et al. A practical method for position-dependent Compton-scatter correction in single photon emission CT. IEEE Trans Med Imaging 1991;10(3):408-12.
25. Macey DJ, Grant EJ, Bayouth JE, et al. Improved conjugate view quantitation of I-131 by subtraction of scatter and septal penetration events with a triple energy window method. Med Phys 1995;22(10):1637-43.
26. Fleming JS. A technique for the measurement of activity using a gamma camera and computer. Phys Med Biol 1979;24(1):176-80.
27. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;3(4):253-5.
28. Siegel JA, Lee RE, Pawlyk DA, et al. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl Med Biol 1989;16(6):553-9.
29. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;25:638-43.
30. Shepp LA, Vardi Y. Maximum likelihood reconstruction for emission tomography. IEEE Trans Med Imaging 1982;1:113-22.
31. Lange K, Carson R. EM reconstruction algorithms for emission and transmission tomography. J Comp Assist Tomogr 1984;8:306-16.
32. Stabin MG, Siegel JA, Sparks RB. Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters. Cancer Biother Radiopharm 2002;17(5):535-43.
33. Bolch WE, Patton PW, Shah AP, et al. Considerations of anthropomorphic, tissue volume, and tissue mass scaling for improved patient specificity of skeletal S values. Med Phys 2002;29:1054-70.
34. Brindle JM, Myers SL, Bolch WE. Correlations of total pelvic spongiosa volume with both anthropometric parameters and computed tomography-based skeletal size measurements. Cancer Biother Radiopharm 2006;21(4):352-63.
35. Brindle JM, Trindade AA, Shah AP, et al. Linear regression model for predicting patient-specific total skeletal spongiosa volume for use in molecular radiotherapy dosimetry. J Nucl Med 2006;47(11):1875-83.
36. Pichardo JC, Trindade AA, Brindle JM, et al. Method for estimating skeletal spongiosa volume and active marrow mass in the adult male and adult female. J Nucl Med 2007;48(11):1880-8.
37. Bolch WE, Eckerman KF, Sgouros G, et al. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med 2009;50(3):477-84.
38. Glatting G, Kletting P, Reske SN, et al. Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test. Med Phys 2007;34(11):4285-92.
39. Snyder WS, Ford MR, Warner GG, et al. "S", absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: The Society of Nuclear Medicine; 1975.
40. ICRP Publication 30, Part 1, Limits for intakes of radionuclides by workers. Ottawa: International Commission on Radiological Protection. 1980
41. Stabin MG MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37(3):538-46.
42. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023-7.
43. Beddoe AH, Darley PJ, Spiers FW. Measurements of trabecular bone structure in man. Phys Med Biol 1976;21(4):589-607.
44. Beddoe AH. Measurements of the microscopic structure of cortical bone. Phys Med Biol 1977;22(2):298-308.
45. Whitwell JR, Spiers FW. Calculated beta-ray dose factors for trabecular bone. Phys Med Biol 1976;21(1):16-38.
46. Eckerman KF, Stabin MG. Electron absorbed fractions and dose conversion factors for red marrow and bone by skeletal regions. Health Phys 2000;78(2):199-214.
47. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85(3):294-310.
48. Bouchet LG, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within cortical bone. J Nucl Med 1999;40(12):2115-24.
49. Bouchet LG, Jokisch DW, Bolch WE. A three-dimensional transport model for determining absorberd fractions of energy for electrons within trabecular bone. J Nucl Med 1999;40(11):1947-66.
50. Bouchet LG, Bolch WE, Howell RW, et al. S values for radionuclides localized within the skeleton. J Nucl Med 2000;41(1):189-212.
51. Watchman CJ, Jokisch DW, Patton PW, et al. Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male. J Nucl Med 2005;46(7):1171-85.
52. Stabin MG, Eckerman KF, Bolch WE, et al. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 2002;17(4):427-33.
53. Sgouros G, Stabin M, Erdi Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000;27(9):2150-64.
54. Shah AP, Bolch WE, Rajon DA, et al. A paired-image radiation transport model for skeletal dosimetry.J Nucl Med 2005;46(2):344-53.
55. Petoussi-Henss N, Bolch WE, Zankl M, et al. Patient-specific scaling of reference S-values for cross-organ radionuclide S-values: What is appropriate? Radiat Prot Dosim 2007;127:192-6.
56. Shen S, DeNardo GL, Sgouros G, et al. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999;40(12):2102-6.
57. Sgouros G Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34(4):689-94.
58. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm 1990;3(4):213-33.
59. Sgouros G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer. J Nucl Med 2005;46(5):899-900.
60. Hindorf C, Lindén O, Tennvall J, et al. Time dependence of activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer 2002;94(4 suppl):1235-9.
61. Sgouros G, Jureidini IM, Scott AM, et al. Bone marrow dosimetry: regional variability of marrow-localizing antibody. J Nucl Med 1996;37:695-8.
62. Traino AC, Ferrari M, Cremonesi M, et al. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol 2007;52:5231-48.
63. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 131I-MIBG. J Nucl Med 2001;42(11):1713-21.
64. Buckley SE, Chittenden S, Saran FH, et al. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009;50(9):1518-24.
65. Seldin DW. Techniques for using bexxar for the treatment of non-Hodgkin's lymphoma. J Nucl Med Technol 2002;30(3):109-14.
66. Divoli A, Chiavassa S, Ferrer L, et al. Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methods. J Nucl Med 2009;50(2):316-23.
67. Kwok CS. Backscattering of low energy electrons at bone/bone marrow interfaces. Antibody Immunoconjug Radiopharm 1990;3(4):251-7.
68. Kwok CS, Bialobzyski PJ, Yu SK. Effect of tissue inhomogneity on dose distribution of continuous activity of low-energy electrons in bone marrow cavities with different topologies. Med Phys 1991;18(3):533-41.
69. Watchman CJ, Bourke VA, Lyon JR, et al. Spatial distribution of blood vessels and CD34+ hematopoietic stem and progenitor cells within the marrow cavities of human cancellous bone. J Nucl Med 2007;48(4):645-54.
70. Daldrup-Link HE, Henning T, Link TM. MR imaging of therapyinduced changes of bone marrow. Eur Radiol 2007;17:743-61.
71. Beshara S, Sörensen J, Lubberink M, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003;120:853-9.
72. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med 2006;47(10):1592-8.
73. Blumenthal RD, Lew W, Juweid M, et al. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 2000;88(2):333-43.
74. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 2003;44(1):67-76.
75. Bertho JM, Demarquay C, Frick J, et al. Level of flt3-level in plasma: a possible new bio-indicator for radiation-induced aplasia. Int J Radiat Biol 2001;77(6):703-12.